FDA approves Abbvie's preventative migraine tablet

Another preventive migraine treatment is ready for the US market, after the FDA accepted Abbvie's drug Qulipta on Tuesday.
Photo: Abbvie / PR
Photo: Abbvie / PR

Competition on the market for migraine prevention is heating up as yet another treatment has slipped through the eye of the needle at the US Food and Drug Administration (FDA).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading